You are here:

umeclidinium / vilanterol (Anoro)

Advice

following a re-submission:

umeclidinium/vilanterol (Anoro®) is accepted for use within NHS Scotland.

Indication under review: As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.  Two randomised controlled studies demonstrated that after 24 weeks of treatment, umeclidinium/vilanterol significantly improved lung function compared with an inhaled long-acting muscarinic antagonist in patients with moderate to very severe COPD. Indirect comparisons demonstrated comparable efficacy with other combinations of long acting muscarinic antagonist plus long acting beta agonist.
 

Drug Details

Drug Name: umeclidinium / vilanterol (Anoro)
SMC Drug ID: 978/14
Manufacturer: GlaxoSmithKline UK Ltd
Indication: As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 9 February 2015

Archived Advice

Full submission 11 August 2014

Back